← Oncology Approval Tracker

FDA DECISION ·

Trodelvy + Keytruda / Keytruda Qlex

sacituzumab govitecan-hziy with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph · Gilead Sciences / Merck

FDA approvalNew or expanded indicationBreast cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

First-line combination for adults with unresectable locally advanced or metastatic TNBC whose tumors have a PD-L1 combined positive score (CPS) of at least 10 on an FDA-authorized test.

LAMPGEN ANALYSIS

Why it matters

This gives the PD-L1-selected first-line population an ADC and checkpoint inhibitor combination. ASCENT-04 and ASCENT-03 answer different treatment questions.

What research teams should watch

Verify the PD-L1 assay and CPS, record the correct pembrolizumab formulation and plan surveillance for both ADC and immune-mediated toxicity.

PRIMARY RECORDS

Sources